Trial Profile
Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Ponesimod (Primary) ; Teriflunomide
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms OPTIMUM
- Sponsors Actelion Pharmaceuticals
- 08 May 2023 Results from NCT02634307 and NCT02425644 , comparing DRF versus PON and DRF versus TERI for clinical and radiological outcomes, published in the CNS Drugs
- 27 Apr 2023 Results (n=239) assessing the clinical and magnetic resonance imaging (MRI) outcomes in RMS patients at 48 weeks of follow-up after short-term interruption and re-initiation of ponesimod treatment, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 25 Feb 2023 Results of an analysis assessing treatment effects of ponesimod and teriflunomide on regional atrophy by quantifying changes in volume of deep gray matter structures presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2023